Inflammatory Biomarkers in Seizure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-31

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure.
2. Possible role to predict the prognosis of patients with epileptic seizure

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure

NCT05571371

UNKNOWN

Assessment of Severity and Prognosis for Patients With Status Epileptics(SE)

NCT02269137

Status Epileptics

UNKNOWN

Monitoring Patients With Uncontrolled Epilepsy

NCT00001149

Epilepsy Seizures

COMPLETED

Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings

NCT00071305

Epilepsy

COMPLETED

Wearable Devices to Monitor Seizures in Autoimmune Epilepsy

NCT05627661

Autoimmune Epilepsy Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Epilepsy is one of the most prevalent neurological disorders characterized by frequent somatic and psychiatric co-morbidities(1). Accurate diagnosis of epilepsy is challenging because clinicians rarely observe the actual clinical seizure outside of the hospital. Furthermore, psychogenic nonepileptic seizures (PNES) can mimic epileptic seizures (ES), leading to erroneous diagnosis and inappropriate treatments. A critical gap in the diagnostic assessment of seizures is a blood test that can distinguish ES from PNES (2). Both diagnoses were confirmed by the gold standard diagnostic method video/electroencephalogram (EEG) monitoring (3). Taking all in to account, the notion that neuro-inflammation is the key pathology behind focal epileptic seizure initiation and maintenance and the dynamic and adaptative process of neuro -inflammation is associated with blood-brain-barrier disruption and glial activation is no longer a surprise (4).

Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates immune responses via apoptosis, with lower levels associated with severe infection, including sepsis (5). Monocyte chemoattractant protein-2 (MCP-2) has been well recognized to participate in immune regulation via binding to chemokine receptors and activation chemotaxis in lymphocytes T, natural killer (NK) cells, and monocytes therefore contributing to the pathogenesis of monocyte-dependent tissue injury (6). Hence, MCP-2 overexpression could result in an increased immune response. Further, since increased levels of MCP-2 have been observed in patients with Alzheimer's disease, this may further support the existence of the biodirections relationship between neurodegeneration and seizures/epilepsy (7).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Biomarkers in Seizures

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Epileptic seizure

patients diagnosed as epileptic seizure are aged \>12 years

Inflammatory serum biomarkers

Intervention Type DIAGNOSTIC_TEST

Measuring inflammatory serum biomarkers by ELISA

Psychogenic non-epileptic seizure

patients diagnosed as psychogenic non-epileptic seizure are aged \>12 years

Inflammatory serum biomarkers

Intervention Type DIAGNOSTIC_TEST

Measuring inflammatory serum biomarkers by ELISA

Normal healthy control

Heathy control are aged \>12 years with no history of lifetime seizures or suspected seizures or febrile seizure and no treatment with an antiepileptic drug (AED) prior to blood draw

Inflammatory serum biomarkers

Intervention Type DIAGNOSTIC_TEST

Measuring inflammatory serum biomarkers by ELISA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inflammatory serum biomarkers

Measuring inflammatory serum biomarkers by ELISA

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

patients diagnosed as epileptic seizure are aged \>12 years patients diagnosed as psychogenic non-epileptic seizure are aged \>12 years Normal healthy control for comparison. Heathy control are aged \>12 years with no history of lifetime seizures or suspected seizures or febrile seizure and no treatment with an antiepileptic drug (AED) prior to blood draw

Exclusion Criteria

* Neurological criteria: Other CNS disorders including Parkinson's disease, amyotrophic lateral sclerosis ,cerebrovascular stroke, Psychiatric disorders {major depression disorder , generalized anxiety, mania and other psychiatric diseases).

Others: Tumors and cardiovascular

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No